Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978620 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL13204009 | 0.96 | CALCRL (0.93) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL13204026 | 0.92 | CALCRL (0.85) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL2980220 | 0.90 | CALCRL (1.00) | CALCRLCYP3A4 | |
| SCHEMBL2974681 | 0.90 | CALCRL (1.00) | CALCRLCYP3A4 | |
| SCHEMBL13204029 | 0.89 | CALCRL (0.81) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL13204015 | 0.88 | CALCRL (0.79) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL3598516 | 0.88 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL2980028 | 0.88 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 | |
| SCHEMBL2980031 | 0.88 | CALCRL (1.00) | CALCRLCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | claimed |
| EP-1730137-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | Bristol-Myers Squibb Company (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095383-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | claimed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772244-B2 | Therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1730137-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | Bristol-Myers Squibb Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095383-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215576-A1 | Novel therapeutic agents for the treatment of migraine | CALCRL, CALCR, CALCA | CALCRL 1/4885CYP3A4 3330/4885CYP2D6 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.